Canada halts AstraZeneca COVID-19 vaccine for people 55 and under, citing 'uncertainty' on blood clots
Canada's 13 provinces and territories, on advice from the National Advisory Committee on Immunization, suspended use of AstraZeneca's vaccine on people 55 and younger Monday. The advisory committee said its recommendation was a "precautionary measure" due to "rare" cases of blood clots in Europe, mostly affecting women under 55. "There is substantial uncertainty about the benefit of providing AstraZeneca COVID-19 vaccines to adults under 55 given the potential risks," said Dr. Shelley Deeks, the committee's vice chair.
AstraZeneca is a relatively small part of Canada's COVID-19 vaccine strategy, but it is hugely important for the global vaccination effort and is widely used in Britain. Europe's drug regulator said there is no evidence of an overall increase in blood clots and the vaccine is safe and effective to use. Canadian officials said they want more information about the blood clots, especially in young women. There have been no reports of blood clots in Canada, and the country is still using the vaccine for those over 55.
AstraZeneca's "vaccine has had all the ups and downs," Dr. Caroline Quach-Thanh, chair of the National Advisory Committee on Immunization, told reporters Monday. "It looks like a roller coaster." Canada approved the vaccine, developed by Oxford University, in late February, but only for people under 65. When British data came in showing its effectiveness on older people, Canada reversed itself. Now it has changed its advice again.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"The messaging has been brutal overall," Dr. Andrew Morris, a professor of infectious diseases at the University of Toronto, tells The Associated Press. "I am fearful it is toast. It shouldn't be."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
US charges Indian tycoon with bribery, fraud
Speed Read Indian billionaire Gautam Adani has been indicted by US prosecutors for his role in a $265 million scheme to secure solar energy deals
By Peter Weber, The Week US Published
-
Boeing machinists approve contract, end strike
Speed Read The company's largest union approved the new contract offer, ending a seven-week strike
By Peter Weber, The Week US Published
-
US economy still strong in final preelection report
Speed Read It grew at a solid 2.8% annual rate from July through September
By Peter Weber, The Week US Published
-
Boeing machinists reject deal, continue strike
Speed Read The rejection came the same day Boeing reported a $6.2 billion quarterly loss
By Peter Weber, The Week US Published
-
Ports reopen after dockworkers halt strike
Speed Read The 36 ports that closed this week, from Maine to Texas, will start reopening today
By Peter Weber, The Week US Published
-
Empty-nest boomers aren't selling their big homes
Speed Read Most Americans 60 and older do not intend to move, according to a recent survey
By Peter Weber, The Week US Published
-
Brazil accuses Musk of 'disinformation campaign'
Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
By Rafi Schwartz, The Week US Published
-
Disney board fends off Peltz infiltration bid
Speed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
By Rafi Schwartz, The Week US Published